|
|
|
|
|
|
Sponsors and Collaborators: |
Maastricht University Medical Center ZonMw: The Netherlands Organisation for Health Research and Development |
Information provided by: | Maastricht University Medical Center |
ClinicalTrials.gov Identifier: | NCT00402623 |
The exact cause of the chronic lung disease sarcoidosis is still unknown. Consequently, a complete efficacious treatment is still not available. Earlier studies indicate an important key role for oxidative stress, i.e. an imbalance between the production of and the protection against ROS, in the etiology of sarcoidosis. Antioxidants, needed for protection against ROS, are indeed lower in sarcoidosis. Therefore, antioxidant therapy to strengthen the reduced antioxidant defense might be efficacious in sarcoidosis treatment. Since ROS are also capable of initiating and mediating inflammation, antioxidant therapy might also mitigate the elevated inflammation that occurs in sarcoidosis. The flavonoid quercetin possesses both anti-oxidative and anti-inflammatory capacities and might therefore serve as a good candidate for antioxidant therapy in sarcoidosis.
Therefore, the aim of the present study is to determine the effect of quercetin supplementation in sarcoidosis patients on markers of both oxidative stress and inflammation.
Condition | Intervention |
Sarcoidosis |
Dietary Supplement: quercetin Other: placebo |
MedlinePlus related topics: | Antioxidants Sarcoidosis Stress |
ChemIDplus related topics: | Quercetin |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | The Effect of Quercetin on the Increased Inflammatory and Decreased Antioxidant Status in Sarcoidosis |
Enrollment: | 18 |
Study Start Date: | January 2006 |
Study Completion Date: | January 2006 |
Primary Completion Date: | January 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Placebo Comparator
placebo
|
Other: placebo |
2: Active Comparator
quercetin (food supplement)
|
Dietary Supplement: quercetin
1000 mg quercetin within 24 hours
|
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Netherlands | |||||
Maastricht University | |||||
Maastricht, Netherlands, 6200 MD |
Maastricht University Medical Center |
ZonMw: The Netherlands Organisation for Health Research and Development |
Study Chair: | Aalt Bast, PhD | Maastricht University Medical Center |
Principal Investigator: | Agnes W Boots, PhD | Maastricht University Medical Center |
Study Director: | Guido R Haenen, PhD | Maastricht University Medical Center |
Responsible Party: | Maastricht University ( Dr. A.W. Boots ) |
Study ID Numbers: | MEC 05.142.5 |
First Received: | November 20, 2006 |
Last Updated: | February 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00402623 |
Health Authority: | Netherlands: The Central Committee on Research Involving Human Subjects (CCMO) |
|
|
|
|